BVXV News and Press, BiondVax Pharmaceuticals Ltd. From 02/07/23

The COVID-19 pandemic was a major reminder of just how problematic infectious diseases can be, especially if we aren’t intimately aware of their spread patterns. Only a few months after the disease was discovered in Wuhan, China , significant chunks of the world were shut down to avoid ...

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidat...

BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will present at the BIO CEO & Inves...

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd . ( Nasdaq: BVXV ), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment o...

Macular degeneration is an eye disorder that commonly affects people aged 50 years and older. It occurs when the inner layers of the macula, a region of the retina that provides the eye with a clear vision in the direct line of sight, begin to break down and function less effectively. Although w...

BiondVax’s preclinical proof-of-concept study was designed to mimic a real-world situation regarding at-risk groups, including the elderly, people with comorbidities, the immunocompromised, travelers, those attending densely packed social events, and front-line healthcare workers The stu...

A study conducted by researchers at Corewell Health East has revealed that toddlers and infants have higher chances of experiencing severe health outcomes in the face of the so-called “ tripledemic , ” which is comprised of flu, RSV and COVID. Three years after COVID-19 first reare...

Current monoclonal antibody therapies less effective against emerging COVID-19 variants BiondVax is developing an inhaled nanosized antibody (NanoAb) therapy for COVID-19 with human clinical Phase 1/2a results anticipated in 2023 The global monoclonal antibodies market was valued at $185.5 bi...

If you’re looking for penny stocks to buy, you’re likely among the hundreds of traders looking for catalysts. These might come in the form of speculative rumors, SEC filings, or, in today’s case, press releases. They are one of the quickest ways to find out what’s goin...

COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of BiondVax’s COVID-19 NanoAb as prophylactic and therapeutic drug; Previously announced data ind...